Skip to main content
Industrial Research And Consultancy Centre

The treatment, called NexCAR19, raises hopes that this transformative class of medicine will become more readily available in low- and middle-income countries.

Click Here to Know More

A small Indian biotechnology company is producing a home-grown version of a cutting-edge cancer treatment known as chimeric antigen receptor (CAR) T-cell therapy that was pioneered in the United States. CAR-T therapies are used mainly to treat blood cancers and have burgeoned in the past few years. The Indian CAR-T therapy costs one-tenth that of comparable commercial products available globally.

More Details Here..